JonesResearch analyst Catherine Novack initiated coverage of Omega Therapeutics with a Buy rating and $11 price target. Omega is an epigenetic medicine company with an initial focus on MYC dysregulation in cancer, the analyst tells investors in a research note. The firm sees "massive commercial upside" if Omega’s approach is successful and says the company’s numerous preclinical candidates could lead to strategic partnerships and serve as sources of non-dilutive funding.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OMGA:
- Omega Therapeutics price target raised to $10 from $8 at Piper Sandler
- Omega Therapeutics reports Q4 EPS (64c), consensus (63c)
- Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Omega Therapeutics chairman Afeyan buys $19.2M in common stock
- Omega Therapeutics announces $40M registered direct offering
